(Invited) Magnetic Relaxation Nanoparticle Biosensor for Dosimetric, Longitudinal Biochemical Monitoring In Vivo (2020)

Introduction: Harnessing the diversity of sensing platforms for applications in complex environments has been an ongoing challenge in biosensing. Most techniques exhibit limitations ranging from biocompatibility, sensitivity, and signal transduction through opaque media, to longevity under non-laboratory conditions. Through multidisciplinary advances in nanoscience and medical devices, we have developed an implant for the measurement of biomarkers using a magnetic particle assay platform 1,2 . Exposure to target induces a switch from a dispersed to an assembled state with a corresponding change in magnetic relaxation properties allowing for robust contrast. Current applications focus on diagnostics in chronic cardiac disease and spikes in biomarker presence frequently missed by serial sampling. We address design parameters for sensing functionality, tunability, and degradation to lay the groundwork for multi-month implantation in vivo . Materials and Methods: Particle core materials provided magnetic contrast while biological functionality was tuned by surface ligands for affinity toward multivalent targets (Figure 1a). Polyclonal antibodies were conjugated to superparamagnetic iron oxide nanoparticles (20-50 nm) by maleimide-thiol chemistry. Proton Magnetic Relaxation measurements were acquired on a custom-made, single-sided, inhomogeneous field relaxometer (0.43 Tesla, 25°C, NMR MOUSE) fitted with a programmable robotic scanning stage 3 . A Carr-Purcell-Meiboom-Gill pulse sequence was used: TE = 0.035 ms, 5454 echoes, 15 scans, TR = 6 s. Relaxation times were determined by single exponential fit to echo peak intensities with a custom MATLAB script. Delrin diffusion devices were filled with particle colloidal suspension and sealed with 30 nm pore polycarbonate semi-permeable membranes via double-sided, pressure-sensitive adhesive (Figure 1b). Devices were exposed to target while sensor response was read every 90-120 minutes for up to 48 hrs. Degradation was measured by quantitating loss of ligand from the surface (ELISA) and changes in sensor performance after elevated temperature storage (37°C) for up to 12 weeks. Results and Discussion: Ligand valency was tuned over an order of magnitude (4-40 Antibodies/Particle) by varying bioconjugation strategies and reagents. Conjugation stability under standard storage conditions indicated a lifetime &gt;5 months by isolating free from bound protein by centrifugation. A maximum 1% of conjugated ligand was released, minimally decreasing valency and sensor functionality. Assay performance showed prozone agglutination behavior with quantitative exposure ranging from 50-2000 ng/mL of target and contrast in &lt;2 hrs. Device dosimeter performance was validated for a cardiac Myoglobin model. Saturation was tuned from 4 to 12 μg/mL*hrs corresponding with 8 to &gt;24 hrs of continuous biomarker elevation at 0-500 ng/mL. 4 hr equilibration and irreversible dosimeter signal stability post-exposure for &gt;12 hrs was also observed (Figure 1c). Biochemical and aggregation performance degradation parameters were evaluated. Over 6.5 weeks of elevated temperature storage, 1.8% of the conjugated antibody was unbound. Sensor longitudinal performance on exposure to target over 12 weeks of incubation showed a monotonically decreasing response magnitude and rate (Figure 1d). Exponential fit to sensor response decay curve predicts a 29 week “switch” (on/off) sensor lifetime for an infarction model (500 ng/mL Myo). These results indicate our sensor can be derivatized for a cardiac biomarker with usable sensitivity and saturation dosimeter response corresponding to elevations expected in a Myocardial Infarction (MI). Device performance can be tuned by matching sensor characteristics with the physiological range of target sensitivity and saturation desired. By tuning bioconjugation strategies we enhanced the performance of the biosensor by an order of magnitude over prior studies. Sensor lifetime and nanostructure degradation studies have shown the limiting performance factor is not the loss of ligand from the surface of the particles but rather the loss of binding activity as seen in elevated temperature experiments. Conclusions: This implant has the potential to broaden diagnostics in personalized medicine by addressing the hurdles of longevity and robust sensor signal stability in complex environments. In situ diagnostics offer continuous sentineling of critical biomarkers, providing a deeper understanding of local biology in dynamic, heterogeneous systems. This monitoring provides valuable timescale data to clinicians with insight into their patients’ lab results for early intervention and data collection throughout treatment. This implant has the capacity to bridge the gap between lab and clinical grade sensors, significantly improving interventional medicine by leveraging the robust and tunable nature of magnetic relaxation particle assays. References: Daniel KD, Kim GY, Vassiliou CC, et al. Implantable diagnostic device for cancer monitoring. Biosens Bioelectron . 2009;24:3252-3257. doi:10.1016/j.bios.2009.04.010 Ling Y, Pong T, Vassiliou CC, Huang PL, Cima MJ. Implantable magnetic relaxation sensors measure cumulative exposure to cardiac biomarkers. Nat Biotechnol . 2011;29(3):273-277. doi:10.1038/nbt.1780 Blumich B, Blumler P, Eidmann G, et al. The NMR-MOUSE: Construction, Excitation, and Applications. Magn Reson Imaging . 1998;16(98):479-484. Figure 1